Region Midtjylland

Running trials

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· Source

• Recruiting

  AMBITION 3: A research study investigating how well zenagamtide at higher dose levels lowers blood sugar and body weight compared to semaglutide in people with type 2 diabetes treated with metformin, SGLT2i, or both

  2026-525472-26-00· Phase 3· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Source

• Recruiting

  A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

  NCT07830732· Phase 3· Source

• Not yet recruiting

  Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer

  2025-522431-34-00· Phase 2· Source

• Recruiting

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

  NCT07843498· Phase 3· Source

• Not yet recruiting

  bNAbs and Anti-PD-1 in HIV

  NCT07820813· Phase 2· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· Source

• Not yet recruiting

  Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.

  NCT07757412· Phase 2· Source

• Not yet recruiting

  Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma

  2026-527220-27-00· Phase 3· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Source

• Not yet recruiting

  A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease

  2025-524314-29-00· Phase 3· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

  NCT07776509· Phase 3· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· Source

• Not yet recruiting

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  2025-524439-38-00· Phase 2· Source

• Recruiting

  Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  NCT07770841· Phase 3· Source

• Recruiting

  A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

  NCT07619131· Phase 3· Source

• Recruiting

  A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo

  NCT07757087· Phase 1· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Source

• Recruiting

  A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Phase 1· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

  NCT07662109· Phase 3· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· Source

• Recruiting

  Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

  NCT07695701· Phase 4· Source

• Recruiting

  Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure

  NCT07577596· Phase 4· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Source

• Recruiting

  A study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indication

  2025-522362-78-00· Phase 4· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

  2025-524014-29-00· Phase 3· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Phase 2/3· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07509307· Phase 3· Source

• Recruiting

  Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)

  NCT07481175· Phase 1· Source

• Recruiting

  A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07481630· Phase 3· Source

• Recruiting

  Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

  NCT07527195· Phase 1· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Source

• Recruiting

  Impact of Early Thyroid Hormone Replacement on Kidney Function and Health-Related Quality of Life in Patients at Risk of Postoperative Hypothyroidism after Hemithyroidectomy: A Randomised Controlled Trial

  2025-524175-23-00· Phase 4· Source

• Recruiting

  A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma

  2025-521205-41-00· Phase 2· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Source

• Recruiting

  The REVERT-PREDIABETES trial

  2025-522970-35-00· Phase 4· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Source

• Recruiting

  Senicapoc and Perampanel for Newly Diagnosed Glioblastoma

  NCT07284069· Early phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers14 recruiting
• Multiple myeloma7 recruiting
• Acute myeloid leukemia6 recruiting
• Chronic kidney disease6 recruiting
• Type 2 diabetes6 recruiting
• Obesity5 recruiting
• Pancreatic cancer5 recruiting
• Amyloidosis4 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Crohn's disease4 recruiting
• Glioblastoma4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Bladder cancer3 recruiting
• Colorectal cancer3 recruiting
• Follicular lymphoma3 recruiting
• Heart failure3 recruiting
• High blood pressure3 recruiting
• HIV3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Mantle cell lymphoma3 recruiting
• Myelodysplastic syndromes3 recruiting
• Ovarian cancer3 recruiting
• Alzheimer disease2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Kidney cancer2 recruiting
• Lung cancer2 recruiting
• Lupus (SLE)2 recruiting
• Melanoma2 recruiting
• Multiple sclerosis2 recruiting
• Neuroendocrine tumours2 recruiting
• Osteoporosis2 recruiting
• Sarcoma2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Bipolar disorder1 recruiting
• Cervical cancer1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Haemophilia1 recruiting
• Hepatitis B1 recruiting
• Migraine1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Psoriasis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Thalassaemia1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

  NCT07686263· Phase 3· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

  NCT06667687· Phase 1· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Source

• Completed

  A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

  NCT06299826· Phase 2· Source

• Completed

  Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease

  2023-506300-12-00· Phase 4· Source

• Completed

  A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma

  NCT06018129· Phase 1/2· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· Phase 3· Source

• Active, not recruiting

  Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE

  2022-502105-15-00· Phase 2· Source

• Completed

  Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

  NCT05794139· Phase 2· Source

• Recruiting

  A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  NCT05878717· Phase 2/3· Source

• Completed

  Adipose-derived mesenchymal stem cells as local treatment of ulcerative colitis

  2024-518643-38-00· Phase 1/2· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Active, not recruiting

  A Study of Daratumumab

  NCT05438043· Phase 3· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Source

• Active, not recruiting

  IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

  NCT05155254· Phase 3· Source

• Completed

  A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study

  2024-511560-93-00· Phase 3· Source

• Recruiting

  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  NCT05139017· Phase 2/3· Source

• Completed

  Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma

  NCT04246177· Phase 3· Source

• Recruiting

  Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

  NCT04589299· Phase 4· Source

• Completed

  APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

  NCT03997383· Phase 3· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source

• Completed

  Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

  NCT03581773· Phase 2· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

  NCT03201965· Phase 3· Source

• Completed

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· Phase 3· Source

• Completed

  HD21

  NCT02661503· Phase 3· Source